RP Bio lnc

RP Bio lnc's capital structure is characterized by a debt-to-equity ratio of 0.3, indicating a relatively conservative leverage position compared to the industry median of 0.8. The company maintains a current ratio of 1.2, suggesting moderate liquidity, with cash and equivalents amounting to KRW 5.19 billion. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

Profitability metrics reveal a challenging operating environment for RP Bio lnc. The company reported a net loss of KRW 518.07 million and an operating loss of KRW 262.02 million, with a return on equity of -0.51% and a return on assets of -0.32%. These figures fall significantly below the industry median ROE of 12.5% and ROA of 6.2%, highlighting the company's underperformance in generating returns for shareholders and asset utilization.

Geographically, RP Bio lnc's revenue is concentrated in South Korea, with no disclosed international revenue segments. The company's business is entirely within the pharmaceuticals segment, with no diversification across therapeutic areas or product lines. This concentration increases exposure to domestic regulatory and market risks.

Growth trajectory analysis shows a mixed picture. While the company's operating cash flow of KRW 1.73 billion and free cash flow of KRW 630.02 million suggest some operational efficiency, the net loss and negative ROE indicate ongoing challenges in translating cash flow into profitability. The outlook for the current fiscal year (FY) is neutral, with no significant revenue growth expected, and the next FY is projected to show minimal improvement.

Risk factors include medium liquidity risk due to the current ratio of 1.2 and a negative net cash position after debt. The company's dilution risk is assessed as low, with no recent share issuance or ATM/shelf registration activity reported. However, the operating losses and negative returns suggest potential pressure to raise additional capital, which could lead to future dilution.

Recent events include the Q4 2023 financial filing, which disclosed the operating and net losses, as well as the capital expenditure of KRW 514.32 million. No significant regulatory or litigation events were reported in the latest filings, but the company's reliance on a single business segment and geographic market remains a concern.

Free cash flow surged 1,129.3% year-over-year to KRW 5.48 billion, demonstrating significant improvement in cash generation capabilities.

Operating income jumped 839.6% to KRW 5.13 billion, indicating a strong recovery in core operational profitability.

Net income increased 616.2% to KRW 4.68 billion, marking a substantial turnaround from the previous year's net loss.

Long-term debt decreased to KRW 19.45 billion, reflecting a deleveraging trend and improved balance sheet health.

The company maintains a low dilution risk profile, suggesting limited threat to existing shareholder equity value.

Net margin of -1.59% trails the industry median of 3.9%, highlighting persistent challenges in converting revenue to profit.

The company faces high credit risk, which could impair financial stability and increase borrowing costs.

Cash conversion ratio of -3.33 sits in the bottom quartile, signaling poor ability to turn earnings into cash.

Revenue KRW 138.11B, +20,1% YoY; Operating income +49,3% YoY.

• ▍Revenue KRW 138.11B, +20,1% YoY
• ▍Operating income +49,3% YoY
• ▍Net income +13,2% YoY
• ▍Free cash flow +154,3% YoY
• ▍Net margin 3.1%